Edgewise TherapeuticsEWTX
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Employees: 97
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
657% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $140K
97% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 30
50% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 22
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
10.01% more ownership
Funds ownership: 98.82% [Q1] → 108.83% (+10.01%) [Q2]
9% more capital invested
Capital invested by funds: $1.68B [Q1] → $1.83B (+$153M) [Q2]
9% more funds holding
Funds holding: 129 [Q1] → 140 (+11) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
RBC Capital Leonid Timashev 60% 1-year accuracy 18 / 30 met price target | 38%upside $42 | Outperform Maintained | 20 Sept 2024 |
Truist Securities Srikripa Devarakonda 53% 1-year accuracy 10 / 19 met price target | 9%upside $33 | Buy Maintained | 19 Sept 2024 |
RBC Capital Leonid Timashev 60% 1-year accuracy 18 / 30 met price target | 6%upside $32 | Outperform Maintained | 17 Sept 2024 |
Wedbush Laura Chico 53% 1-year accuracy 31 / 59 met price target | 2%upside $31 | Outperform Reiterated | 16 Aug 2024 |
JP Morgan Tessa Romero 63% 1-year accuracy 12 / 19 met price target | 2%upside $31 | Overweight Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 12 articles about EWTX published over the past 30 days